story of the week
Toripalimab vs High-Dose Interferon-α2b as Adjuvant Therapy for Resected Mucosal Melanoma
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Annals of Oncology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Toripalimab (anti-PD-1) versus high-dose interferon-α2b as adjuvant therapy in resected mucosal melanoma: a phase II randomized trial
Ann. Oncol 2022 Oct 01;33(10)1061-1070, B Lian, L Si, ZH Chi, XN Sheng, Y Kong, X Wang, H Tian, K Li, LL Mao, X Bai, BX Tang, XQ Yan, SM Li, L Zhou, J Dai, XW Tang, FW Ran, S Yao, J Guo, CL CuiFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.